Introduction G. Hardavella (Athens, Greece), M. Pereira Catarata (Porto, Portugal)
| |
Introduction R. Huber (Munich, Germany), J. Domagala-Kulawik (Warszawa, Poland)
| |
Discussion G. Hardavella (Athens, Greece), S. Nava (Bologna (BO), Italy), A. Toffart (Grenoble, France), Y. Libert (Brussels, Belgium)
| |
Welcome G. Hardavella (Athens, Greece)
| |
High Prevalence and impact of lung cancer in Surfactant related gene mutation carriers A. BRUDON (PARIS, France), N. Nathan (PARIS, France), M. Legendre (PARIS, France), S. Amselem (PARIS, France), J. Bermudez (MARSEILLE, France), D. Bouvry (BOBIGNY, France), J. Cadranel (PARIS, France), A. Cazes (PARIS, France), T. Degot (STRASBOURG, France), C. Delestrain (CRETEIL, France), R. Diesler (BRON, France), R. Epaud (CRETEIL, France), P. Fanen (CRETEIL, France), A. Gondouin (BESANCON, France), A. Guillaumot (VANDOEUVRE-LES-NANCY, France), S. Hirschi (STRASBOURG, France), S. Leroy (NICE, France), S. Marchand-Adam (TOURS, France), H. Nunes (BOBIGNY, France), C. Picard (SURESNES, France), G. Prévot (TOULOUSE, France), M. Reynaud (MARSEILLE, France), P. De Vuyst (BRUXELLES, Belgium), L. Wemeau (LILLE, France), B. Crestani (PARIS, France), G. Zalcman (PARIS, France), V. Cottin (BRON, France), R. Borie (PARIS, France)
| |
AI in lung cancer: potential implications for patient care L. Dercle (New York, United States)
| |
AI in lung cancer screening: the radiologist’s spotlight A. Snoeckx (Edegem (Antwerp), Belgium)
| |
Evaluation of prognostic factors for patients who underwent pneumonectomy for non-small cell lung cancer G. Batihan (Izmir, Turkey), K. Ceylan (Izmir, Turkey), S. Kaya (Izmir, Turkey)
| |
Influence of the Surgeons’ Seniority in the Quality of Life of Patients with Prolonged Air Leaks (PAL) after Lobectomy for Lung Cancer L. Bertolaccini (Milan, Italy), O. Ciani (Milan, Italy), E. Prisciandaro (Milan, Italy), M. Lucchi (Pisa, Italy), F. Zaraca (Bozen/bolzano, Italy), R. Crisci (Teramo, Italy), R. Tarricone (Milan, Italy), L. Spaggiari (Milan, Italy)
| |
Discussion and Q&A
| |
Pneumonitis and radiotherapy: diagnosis and management K. Sreter (Zagreb, Croatia)
| |
Pulmonary toxicity associated with antineoplastic therapy: Molecular targeted agents M. Oliveira Fernandes (Matosinhos, Portugal)
| |
Immune-checkpoint inhibitors: diagnosis and management of pneumonitis in lung cancer patients J. Cadranel (Paris Cedex 20, France)
| |
Status and future perspective of biomarkers in early detection of lung cancer T. Blum (Berlin, Germany)
| |
Early interventions of lung cancer N. Zhong (Guangzhou (Guangdong), China)
| |
Cancer Associated Thrombosis:how many lung cancer patients seen in clinical practice would be eligible to a DOAC randomized controlled trial? B. Petit (Saint Etienne, France), V. Mismetti (Saint Etienne, France), S. Soudet (Amiens, France), G. Poenou (Paris, France), E. Zarrat (Amiens, France), T. Machuron (Saint-Etienne, France), S. Acassat (Saint-Etienne, France), L. Plaisance (Paris, France), H. Helfer (Paris, France), C. Le Hello (Saint-Etienne, France), M. Sevestre (Amiens, France), I. Mahé (Paris, France), L. Bertoletti (Saint-Etienne, France)
| |
Baseline characteristics and Outcomes in Patients with Venous Thromboembolism and Active Lung Cancer – a Nationwide Cohort Study in France L. Bertoletti (Saint Etienne Cedex, France), G. Gusto (Paris, France), A. Khachatryan (London, United Kingdom), N. Quignot (Paris, France), J. Chaves (Madrid, Spain), A. Moniot (Paris, France), R. Mokgokong (London, United Kingdom), I. Mahé (Paris, France)
| |
Discussion
| |
Late Breaking Abstract - Safety and feasibility of a novel externally cooled bronchoscopic radiofrequency ablation catheter for ablation of peripheral lung tumours: a first-in-human dose escalation study D. Steinfort (Melbourne, Australia), P. Antippa (Melbourne, Australia), K. Rangamuwa (Melbourne, Australia), L. Irving (Melbourne, Australia), M. Christie (Melbourne, Australia), E. Chan (Melbourne, Australia), D. Tanaka (Cupertino, United States), K. Yoneda (Sacramento, United States), J. Christie (Melbourne, Australia), F. Herth (Heidelberg, Germany), S. Raina (Santa Clara, United States)
| |
Late Breaking Abstract - Incidence of lung cancer in Chronic Obstructive Pulmonary Disease (COPD) patients: Prognostic factors and survival analysis P. Niyomthong (Phrae, Thailand)
| |
Diagnosing non-small cell lung cancer by exhaled-breath profiling using an electronic nose: a multicentre validation study. S. Kort (Enschede, Netherlands), M. Brusse - Keizer (Enschede, Netherlands), H. Schouwink (Enschede, Netherlands), E. Citgez (Enschede, Netherlands), F. De Jongh (Enschede, Netherlands), J. Van Putten (Groningen, Netherlands), B. Van Den Borne (Eindhoven, Netherlands), L. Kastelijn (Utrecht, Netherlands), D. Stolz (Basel, Switzerland), M. Schuurbiers (Nijmegen, Netherlands), M. Van Den Heuvel (Nijmegen, Netherlands), W. Van Geffen (Leeuwarden, Netherlands), J. Van Der Palen (Leeuwarden, Netherlands)
| |
A novel method exhale breath fingerprinting for lung cancer diagnosis by selected ion monitoring mode L. Pelit (Izmir, Turkey), T. Dizdas (Izmir, Turkey), A. Arin (Izmir, Turkey), S. Özgür (Izmir, Turkey), I. Erbas (Izmir, Turkey), O. Goksel (Izmir, Turkey), F. Pelit (Izmir, Turkey), B. Ordin (Izmir, Turkey), H. Karakus (Izmir, Turkey), A. Gursoy (Izmir, Turkey), F. Ertas (Izmir, Turkey), T. Göksel (Izmir, Turkey)
| |
Radiology quality assurance in the Yorkshire Lung Screening Trial. S. Upperton (Leeds, United Kingdom), C. Bradley (Craigavon, United Kingdom), B. Bhartia (Leeds, United Kingdom), P. Crosbie (Manchester, United Kingdom), M. Darby (Leeds, United Kingdom), R. Gabe (London, United Kingdom), N. Hancock (Leeds, United Kingdom), M. Kennedy (Leeds, United Kingdom), M. Callister (Leeds, United Kingdom)
| |
Pilot lung cancer screening program results in Serbia during 1-year period J. Djekic Malbasa (Novi Sad, Republic of Serbia), T. Kovacevic (Novi Sad, Republic of Serbia), D. Bokan (Novi Sad, Republic of Serbia), B. Zaric (Novi Sad, Republic of Serbia), S. Bojanic (Novi Sad, Republic of Serbia), D. Dragisic (Novi Sad, Republic of Serbia)
| |
Radiomics to increase the effectiveness of lung cancer screening programs. Radiolung preliminary results. A. Rosell Gratacos (Badalona (Barcelona), Spain), S. Baeza (Badalona (Barcelona), Spain), S. Garcia-Reina (Badalona (Barcelona), Spain), J. Mate (Badalona (Barcelona), Spain), I. Guasch (Badalona (Barcelona), Spain), I. Nogueira (Badalona (Barcelona), Spain), I. Garcia-Olivé (Badalona (Barcelona), Spain), G. Torres (Barcelona, Spain), C. Sànchez-Ramos (Barcelona, Spain), D. Gil (Barcelona, Spain)
| |
Implementation of lung cancer screening: an European survey J. van Meerbeeck (Edegem (Antwerp), Belgium), A. Snoeckx (Edegem (Antwerp), Belgium)
| |
Diagnostic bronchoscopic procedures: Combined EBUS and EUS-B for lung cancer staging A. Szlubowski (Kraków, Poland)
| |
Intervention Bronchoscopy in the diagnosis and staging of Lung Cancer L. Viola Muñoz (Bogotá, Colombia)
| |
Lung Cancer Screening- time to move forward? L. Seijo Maceiras (Madrid, Spain)
| |
On-chip human microvasculature assay to study extravasation dynamics of lung cancer cells S. Zeinali (Bern, Switzerland), K. Rechberger (Bern, Switzerland), C. Dubey (Bern, Switzerland), R. Gashi (Bern, Switzerland), T. Marti (Bern, Switzerland), P. Dorn (Bern, Switzerland), O. Guenat (Bern, Switzerland)
| |
IGFBP3 inhibits tumour growth and invasion of H1299 lung cancer cells and leads to improved survival in patients with lung cancer A. Frille (Leipzig, Germany), H. Kuhn (Leipzig, Germany), M. Petersen (Leipzig, Germany), J. Meyer (Leipzig, Germany), L. Hofmann (Leipzig, Germany), A. Gläser (Leipzig, Germany), S. Taubenheim (Leipzig, Germany), S. Krämer (Leipzig, Germany), J. Broschewitz (Bremen, Germany), M. Von Laffert (Leipzig, Germany), H. Wirtz (Leipzig, Germany)
| |
Subtype-specific transcription factors are clinically relevant and show distinct therapeutic vulnerabilities in human small cell lung cancer C. Lang (Vienna, Austria), Z. Megyesfalvi (Budapest, Hungary), B. Szeitz (Budapest, Hungary), A. Lantos (Budapest, Hungary), N. Woldmar (Lund, Sweden), Z. Valko (budapest, Hungary), A. Schwendenwein (Vienna, Austria), F. Oberndorfer (Vienna, Austria), N. Barany (Budapest, Hungary), S. Paku (Budapest, Hungary), V. Laszlo (Vienna, Austria), H. Kiss (Budapest, Hungary), E. Bugyik (Budapest, Hungary), B. Ferencz (Budapest, Hungary), K. Dezso (Budapest, Hungary), Z. Lohinai (Budapest, Hungary), J. Moldvay (Budapest, Hungary), J. Fillinger (Budapest, Hungary), G. Galffy (Budapest, Hungary), C. Rivard (Colorado, United States), F. Hirsch (Colorado, United States), L. Brcic (Graz, Austria), H. Popper (Graz, Austria), I. Kern (Golnik, Slovenia), M. Kovacevic (Golnik, Slovenia), J. Skarda (Olomouc / Ostrava, Czech Republic), M. Mittak (Olomouc / Ostrava, Czech Republic), A. Szasz (Budapest, Hungary), L. Pizzatti (Rio de Janeiro, Brazil), K. Bogos (Budapest, Hungary), M. Hoda (Vienna, Austria), K. Hoetzenecker (Vienna, Austria), G. Marko-Varga (Lund, Sweden), P. Horvatovics (Groningner, Netherlands), F. Renyi-Vamos (Budapest, Hungary), T. Klikovits (Vienna, Austria), K. Schelch (Vienna, Austria), M. Rezeli (Lund, Sweden), B. Döme (Budapest, Hungary)
| |
Relationship between clinicopathologic characteristics and spread through air spaces in resected lung adenocarcinoma and squamous cell carcinoma cases T. Tezvergil (Ankara, Turkey), U. Yilmaz (Ankara, Turkey)
| |
Prophylactic use of mini tracheostomy in patients with comorbidities undergoing lung resection I. Karampinis (Athens, Greece), G. Hardavella (Athens, Greece), A. Katsipoulakis (Athens, Greece), N. Anastasiou (Athens, Greece)
| |
Late Breaking Abstract - Prognostic value of the 1-minute sit-to-stand test on postoperative complications in people with lung cancer elected for lung surgery K. Quadflieg (Diepenbeek, Belgium), R. Higgins (Perth, Australia), M. Criel (Genk, Belgium), M. Daenen (Genk, Belgium), D. Ruttens (Genk, Belgium), M. Thomeer (Genk, Belgium), A. Maiorana (Perth, Australia), C. Burtin (Diepenbeek, Belgium), V. Cavalheri (Perth, Australia)
| |
Systematic evaluation of the pulmonary arteries during endobronchial ultrasound (EBUS) in patients with suspected lung cancer a prospective cohort trial. A. Juul (Odense S, Denmark), C. Laursen (Odense S, Denmark), A. Christophersen (Odense S, Denmark), A. Arshad (Odense S, Denmark), S. Luef (Odense S, Denmark), V. Panou (Odense S, Denmark), J. Paaby (Odense S, Denmark), J. Larsen (Odense S, Denmark), J. Reimer (Odense S, Denmark), C. Falster (Odense S, Denmark)
| |
Robotic-assisted navigation bronchoscopy with needle-based confocal laser endomicroscopy (nCLE) for real-time lung cancer detection T. Kramer (Amsterdam, Netherlands), C. Manley (Philadelphia, United States), R. Kumar (Philadelphia, United States), L. Wijmans (Amsterdam, Netherlands), M. De Bruin (Amsterdam, Netherlands), E. Ross (Philadelphia, United States), Y. Gong (Philadelphia, United States), H. Ehya (Philadelphia, United States), P. Bonta (Amsterdam, Netherlands), J. Annema (Amsterdam, Netherlands)
| |
Dyspnoea management in lung cancer: Pandora's box? I. Higginson (London, United Kingdom)
| |
Incorporating immunotherapy in early-stage lung cancer management J. Chorostowska-Wynimko (Warsaw, Poland)
| |
Recent advances in novel targeted therapies for non-small cell lung cancer and implications for current practice J. van Meerbeeck (Edegem (Antwerp), Belgium)
| |
Prevalence and demographics of marijuana users in a Lung Cancer Screening cohort A. Bhamani (London, United Kingdom), J. Dickson (London, United Kingdom), C. Horst (London, United Kingdom), S. Tisi (London, United Kingdom), H. Hall (London, United Kingdom), A. Creamer (London, United Kingdom), R. Prendecki (London, United Kingdom), J. Mccabe (London, United Kingdom), S. Quaife (London, United Kingdom), F. Bojang (London, United Kingdom), D. Arancon (London, United Kingdom), K. Gyertson (London, United Kingdom), A. Mullin (London, United Kingdom), J. Teague (London, United Kingdom), L. Farrelly (London, United Kingdom), A. Hackshaw (London, United Kingdom), S. Janes (London, United Kingdom)
| |
Case 4 incl. panel discussion and Q&A - Author: N. Cetin (Turkey) S. Janes (London, United Kingdom)
| |
Case 3 incl. panel discussion and Q&A - Author: N. Abu Hussein (Switzerland) A. Charpidou (Athens, Greece)
| |
Case 2 incl. panel discussion and Q&A - Author: S. Wickramasinghe (Sri Lanka) S. Janes (London, United Kingdom)
| |
Case 1 incl. panel discussion and Q&A - Author: F. Mei (Italy) A. Charpidou (Athens, Greece)
| |
Communicating the withdrawal of care - Tips to minimize the psychological impact on patient and carer Y. Libert (Brussels, Belgium)
| |
Oncologist and intensivist join forces – How to deliver the conversation together as an MDT (complementary roles) A. Toffart (Grenoble, France)
| |
Presenting information about ‘not for resus’ status: The intensivist’s perspective S. Nava (Bologna (BO), Italy)
| |
Presenting information about ‘not for resus’ status: The oncologist’s/lung cancer specialist’s perspective G. Hardavella (Athens, Greece)
| |
Patient testimonial M. Hennink (Groningen, Netherlands)
| |